mRNA 1010
Alternative Names: mRNA-1010; Quadrivalent seasonal influenza mRNA vaccine - Moderna; Seasonal influenza vaccine - Moderna TherapeuticsLatest Information Update: 29 Mar 2024
At a glance
- Originator Moderna Therapeutics
- Class Influenza virus vaccines; RNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Influenza virus infections
Most Recent Events
- 27 Mar 2024 Moderna Therapeutics announces intention to submit regulatory application for Influenza virus infection in 2024
- 28 Feb 2024 Moderna completes a phase I clinical trials in Influenza virus infections (Prevention) in USA, Australia and United Kingdom (IM) (NCT05585632)
- 29 Jan 2024 Moderna Therapeutics completes a phase II trial for Influenza virus infections (Prevention) in USA (IM) (NCT05606965)